BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211009
DTSTAMP:20260515T220500
CREATED:20210301T101605Z
LAST-MODIFIED:20210301T101605Z
UID:29208-1633392000-1633737599@www.pharmajournalist.com
SUMMARY:9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)
DESCRIPTION:Leveraging next gen technologies beyond conventional biomarker drug discovery \nThe emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology\, immuno-therapies\, data interpretation and unconventional design of clinical trials. \nThe 9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 5th – 8th October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. \nThis conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding the commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers. \nEvent Website: https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/  \nRegistration link:  https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-est-time-zone/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211008
DTSTAMP:20260515T220500
CREATED:20210802T091237Z
LAST-MODIFIED:20210802T091416Z
UID:31169-1633392000-1633651199@www.pharmajournalist.com
SUMMARY:2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit is the only event uniting key B&T cell decision-makers to advance the therapeutic future of autoimmune diseases. \nJoin this community of 60+ pioneers to aid discovery\, development\, optimization and strategy for a new generation of treatment within this area of vastly unmet clinical need. \nThis cross-disciplinary program featuring keynote talks from 32+ clinical KOLs from large pharma\, biotech and academia\, will give you insight into the full therapeutic opportunity of drug candidates against various plasma\, B and T cell targets. \nUnite with other B & T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells\, B cell functions (autoantibody production\, antigen presentation\, T cell help & cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression. \nView our full event guide to see our complete speaker line-up\, latest agenda\, and workshop details. https://ter.li/0zk3pp \nKey Discussions you Can’t Afford to Miss: \n\nDelve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro\, Polyneuron\, Apitope\, NYSCF\, UTHSC & Cabaletta Bio\nDiscover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co\, UCL\, Kyverna\, Immunic AG\, Nurix & GSK\nUncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio\, Cytocom\, Horizon\, AltruBio & Novartis\nExplore targets\, considerations and strategy for targeting autoantibody producing plasma cells\, organ specific and systemic diseases with UCB\, Provention Bio\, IM Therapeutics & Biogen\nOptimize application and patient outlook through combination strategies\, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation\, Bristol-Myers Squibb & Eli Lilly & Co\n\nFind out more https://ter.li/0zk3pp
URL:https://www.pharmajournalist.com/event/2nd-annual-bt-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR